Navigation Links
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Date:5/7/2009

terialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to consummate a strategic transaction on a timeline it believes is acceptable, divests its assets on best-available terms and entirely winds-down its operations; the risk that ADVENTRX will be unable to consummate a strategic or partnering transaction or otherwise raise sufficient capital and will be unable to continue as a going concern, including as a result of negative perceptions of the data from its bioequivalence study of ANX-514; the risk that ADVENTRX's recent cost-containment measures, including the discontinuation of substantially all of its development activities and fundamental business operations and reduction in force to a small, select number of full-time employees, will negatively impact ADVENTRX's ability to consummate a strategic transaction; the potential for regulatory authorities to require additional preclinical and/or clinical activities to support regulatory filings, including prior to the submission or the approval of an NDA for ANX-514, and the impact of increased uncertainty regarding the need for such activities on strategic, partnering and capital-raising transactions; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data, including clinical investigators, expert data monitoring committees, contract laboratories and contract research organizations, may be substandard, or they may fail to perform as expected; difficulties or delays in obtaining regulatory approval for ANX-514, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-514 and other challenges by patent holders during the Section 505(b)(2) process; the risk t
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
4. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
5. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
8. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
9. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
10. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Quebec, July 31, 2014   , 2014 Second ... the prior year , Overall organic growth was 4% for ... injectable products; Bausch + Lomb grew 12% , 2014 ... of 43% , 2014 Second Quarter GAAP Operating Cash ... , Highlights of the Second Quarter , Launched 17 ...
(Date:7/31/2014)... 2014 Auxilium Pharmaceuticals, Inc. ... company, today announced that the Company will receive ... partner Asahi Kasei Pharma Corporation (Asahi Kasei). The ... of a regulatory application to the Japanese Pharmaceutical ... (collagenase clostridium histolyticum) for the treatment of ...
(Date:7/31/2014)... 2014 MarketResearchreports.biz presents this most ... (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, Premixed, And Modern and ... and Forecast (Value and Volume), 2013 - 2019: Market ... growing at an exponential rate worldwide, has become a ... major cause of death of people between 20 years ...
Breaking Medicine Technology:Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 26Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 27Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 28Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 29Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 30Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 31Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 32Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5
... First Pro-Healing Stent Also ... Featured at Annual Symposium, ... the subject of several sessions about,innovation in interventional cardiology strategies ... 2007,which is set for Oct. 20-25 at the Washington Convention ...
... Bono Initiative Aims to Mobilize $25 Million to Eliminate ... Afflicting the Poorest of the Poor, EAST RUTHERFORD, N.J., ... nation,s top ten public relations firms, was,highlighted by President Bill ... for its key role in the fight against diseases of,poverty ...
Cached Medicine Technology:OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007 2President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its 'Stop Neglected Tropical Disease' Campaign 2President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its 'Stop Neglected Tropical Disease' Campaign 3President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its 'Stop Neglected Tropical Disease' Campaign 4
(Date:7/31/2014)... Controlled application of vacuum pressure is a promising approach ... suggests an experimental study in the August issue of ... Congress of Neurological Surgeons . The journal is ... part of Wolters Kluwer Health . , ... injured area of the brainshows promise as a safe ...
(Date:7/31/2014)... and Las Vegas, Nevada (PRWEB) July 31, 2014 ... LaunchKey to provide next generation authentication services to cloud ... secure way to utilize hardware protected multi-factor authentication with ... in the Internet's reliance on password-based authentication. It is ... global data breaches taking place around the globe. Instead ...
(Date:7/31/2014)... Texas (PRWEB) July 31, 2014 The ... Patient Experience Executive Board and four new members ... strengthening its role as the global community of practice ... in healthcare. , Executive board members are industry ... plans, and provide valuable insight into market and industry ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Web Programming ... ISO 9001:2008 certified internet marketing firm, has recently launched ... to make this service affordable for everyone, the company ... the service. , Web Programming Services has tailored ... world of brochure designing and likely expectations of the ...
(Date:7/31/2014)... Steven Reinberg HealthDay Reporter ... Strict regulation of electronic cigarettes isn,t warranted based on ... the contrary, allowing e-cigarettes to compete with regular cigarettes ... after reviewing 81 prior studies on the use and ... evidence suggests that there is a potential for smokers ...
Breaking Medicine News(10 mins):Health News:Vacuum treatment may limit damage after traumatic brain injury 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 2Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3
... trigger urge to smoke, researchers say , WEDNESDAY, Sept. 9 ... component in cigarettes, "tricks" the brain into creating memory associations ... why former smokers miss lighting up when they are in ... from researchers at Baylor College of Medicine are in the ...
... response , WEDNESDAY, Sept. 9 (HealthDay News) -- Early day ... and illnesses at an early age, thereby protecting them from ... the ,hygiene hypothesis," but a new study casts doubt on ... asthma and allergy rates at age 8. , An unexplained ...
... , SOUTHFIELD, Mich., Sept. 9 The Wild ... employee health screenings. While national and local regulations cover finger sticks ... national standards and monitors on-site health screenings or flu shot programs. ... approaches, a new white paper from wellness screening provider Summit Health, ...
... PRINCETON, N.J., Sept. 9 From October 5-9, contact center ... Mandalay Bay Convention Center to attend the sixth annual 2009 ... Produced by the International Customer Management Institute (ICMI), this year,s ... the Customer Experience." Intensive, daylong pre-conference summits for financial services ...
... , CHICAGO, Sept. 9 Morrisey ... high-risk, complex patients outside the acute-care setting. , ... (MCCM(TM)) Continuum of Care software enables organizations to extend their ... are able to reduce unnecessary hospital admissions, emergency department visits ...
... , , , SHREVEPORT, La., ... set out on her life-finding mission with a book contract in her pocket. ... giant in Italy, she was just living. She had no notion that what ... , But life took this Louisiana-raised girl and her endearing ...
Cached Medicine News:Health News:Nicotine Plays Tricks on Brain: Study 2Health News:Day Care May Not Shield Kids From Asthma, Allergies 2Health News:Day Care May Not Shield Kids From Asthma, Allergies 3Health News:Summit Health Helps Employers Navigate the 'Wild West' of Flu Shots and Workplace Health Screenings 2Health News:Global Gathering for Contact Center Professionals to Focus On 'Thinking Forward - The Power of the Customer Experience' at ICMI's Annual Call Center Exhibition Conference and Expo, Oct. 5-9 in Las Vegas 2Health News:Global Gathering for Contact Center Professionals to Focus On 'Thinking Forward - The Power of the Customer Experience' at ICMI's Annual Call Center Exhibition Conference and Expo, Oct. 5-9 in Las Vegas 3Health News:Morrisey Associates Helps Healthcare Organizations Improve Patient Management Outside the Acute-Care Setting 2Health News:Exotic Adventure and Clean Food: The Adventure Cookbook 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... Remels newest member of the Xpect family, Xpect ... and B in one rapid test. The simple-to-perform ... available in 20 minutes. ,The Remel Xpect family ... range of rapid, direct specimen tests that combine ...
Inquire...
Inquire...
Medicine Products: